CTOs on the Move

The DNA Repair Company

www.dnar.com

 
The DNA Repair Company is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.dnar.com
  • 1 Kendall Sq Bldg 300
    Cambridge, MA USA 02139
  • Phone: 617.517.3210

Executives

Name Title Contact Details

Similar Companies

SK pharmteco

Headquartered in Rancho Cordova, California, SK pharmteco is a global contract development and manufacturing organization specializing in the production of active pharmaceutical ingredients (APIs), advanced intermediates, and cell and gene therapy for the pharmaceutical industry. Built on 80 years of experience, our global operations have the capability and capacity to support client needs from development through commercial production. SK pharmteco is owned by SK Inc., the strategic investment arm of South Koreas SK Group.

Progressive Medical

Progressive Medical is a Westerville, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DYNAMIS THERAPEUTICS

DYNAMIS THERAPEUTICS is a Jenkintown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Caliper Life Sciences

Caliper Life Sciences is a Hopkinton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

LAVA Therapeutics

At LAVA, we are focused on applying our expertise in gamma-delta T-cell engagers (TCEs) to transform cancer therapy. We refer to our compounds as gamma-delta bispecific T-cell engagers, or gamma-delta bsTCEs. Our platform generates therapeutics that specifically activate a unique and relatively abundant effector gamma-delta T-cell subset called Vγ9Vδ2 (Vgamma9-Vdelta2) T-cells that have the ability to trigger activity of immune cells of both the innate and adaptive immune system. Our gamma-delta bsTCEs have demonstrated superior efficacy and safety profiles compared to other bsTCE approaches in preclinical studies and show preferential activity against tumor cells thereby potentially limiting toxicity in healthy tissue. To date, we are the only company developing bispecific gamma-delta T-cell engaging antibodies for the treatment of cancer. We are building a pipeline of gamma-delta bsTCEs that have applications in both solid and hematologic malignancies. Our lead program, LAVA-051, targets the tumor specific antigen CD1d, which can be overexpressed in multiple myeloma, chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML), among other tumor types. LAVA-051 will enter a Phase I/IIa study in 1Q21.